Assessment of drug utilization pattern and prescribing quality indicators among chronic kidney disease patients in a tertiary hospital in Northern Ghana
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20261115Keywords:
Chronic kidney disease, Drug utilization pattern, Prescribing quality indicatorsAbstract
Background: Drug utilization research in chronic kidney disease (CKD) patients can help identify drug utilization pattern, and evaluate quality of drug use by comparing to standard prescribing indicators or clinical guidelines. There is dearth of drug utilization study among CKD patients in Ghana, therefore this study aims to assess drug utilization pattern and quality prescribing indicators in CKD patients in Ghana.
Methods: Retrospective study was conducted among CKD patients in the Tamale Teaching Hospital in northern region of Ghana.
Results: Cardiovascular drugs were the commonly utilized across all stages of CKD (n=790,31.7%). Potential appropriate prescribing of antihypertensive agents (93.5%), and renin-angiotensin system (RAS) inhibitors alone (66.1%) were higher compared to combined RAS inhibitor with a diuretic (55.4%), phosphate binders (50.0%) and statins (35.6%). Patients with advance CKD stages received lower RAS inhibitors but higher statins compared to CKD stag-3 patients. There was optimal compliance with inappropriate prescription of dual RAS inhibitors, erythropoietin stimulating agent (ESA) and digoxin. Contraindication of metformin (57.9%) was higher than nonsteroidal anti-inflammatory drugs (NSAIDs) and NSAIDs + RAS inhibitor + diuretic; (1.2%) and (1.1%) respectively.
Conclusions: This study is the first to assess prescribing quality indicators among CKD patients in Ghana and hence will serve as a baseline data for future drug utilization studies in the country. Priority areas for optimal prescribing include RAS inhibitors alone or combined with a diuretic, phosphate binders and statins when indicated. However, there is urgent need to mitigate contraindication prescription of metformin in the CKD patients.
References
Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB. Chronic kidney disease and the global public health agenda : an international consensus. Nat Rev Nephrol. 2024;20:473-85.
WHO. Introduction to Drug Utilization Research. 2003. Available at: https://apps.who.int/iris/handle/10665/42628. Accessed on 12 January 2026.
Alruqayb WS, Paudyal V, Malcolm P, Sarwar A, Aston J, Cox AR. Drug utilisation study in hospitalised chronic kidney disease patients , using World Health Organisation prescribing indicators : an observational study. J Pharm Policy Pract. 2024;17:1-18.
Smits KPJ, Sidorenkov G, Bilo HJG, Bouma M, Ittersum FJ Van. Development and initial validation of prescribing quality indicators for patients with chronic kidney disease. Nephrol Dial Transpl. 2016;1123-30.
Rasmussen L, Wettermark B, Steinke D, Pottegård A. Core concepts in pharmacoepidemiology : Measures of drug utilization based on individual-level drug dispensing data. Pharmacoepidemiol Drug Saf. 2022;31:1015-26.
Kamath L, Hema NG, Himamani S. A study of drug utilisation pattern in patients of chronic kidney disease at a tertiary care hospital. Int J Basic Clin Pharmacol. 2019;8(2):170-5.
Ali A, Kumar P, Ansari JA, Fatima M, Irrum F. A prospective observational study on medication use pattern in patients with risk factors of chronic kidney disease. Asian J Pharm Clin Res. 2021;14(12):1-5.
Oommen JM, Nerurkar DP, Sajith M, Jawale S, Ambike S. Prescription Pattern of Chronic Kidney Disease Patients undergoing Hemodialysis in Tertiary and Private Hospital. J Young Pharm. 2019;11(2):202-6.
Al-jabri MM, Shastry CS, Chand S. Assessment of Drug Utilization Pattern in Chronic Kidney Disease Patients in A Tertiary Care Hospital Based on Who Core Drug Use Indicators. J Glob Pharma Technol. 2019;11:1-9.
Dreischulte T, Grant AM, Mccowan C, Mcanaw JJ, Guthrie B. Quality and safety of medication use in primary care : consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. BMC Clin Pharmacol. 2012;12(1):5.
Martirosya L, Voorham J, Braspenning FMHRJ, Denig BHRWP. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf. 2010;9(4):319-34.
KDIGO. Harmonizing acute and chronic kidney disease de fi nition and classi fi cation: report of a kidney disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2021;100:516-26.
MDCALC. ChroKD-EPI Equations for Glomerular Filtration Rate (GFR). Available at: https;//www.mdcalc.com. Accessed on 12 January 2026.
WHO/WHOCC. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC Classification and DDD Assignment 2024. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2024. 2024. Available at: https://www.whocc.no/atc_ddd_index/. Accessed on 12 January 2026.
Okyere P, Okyere I, Ephraim RKD, Attakorah J, Osafo C, Arhin B, et al. Spectrum and Clinical Characteristics of Renal Diseases in Ghanaian Adults : A 13-Year Retrospective Study. Int J Nephrol. 2020;2020:5-9.
Ovwasa H, Aiwuyo HO, A OCO, Unuigbe E, Rajora N. Epidemiology Trend of Chronic Kidney Disease in a Semi-Urban Tertiary Hospital in Sub-Saharan Africa. Cureus. 2023;15(3):e36912.
Yaw A, Dennis O, George B, Henry A, Awuku Y. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. Pan African Med J. 2014;18:274.
atta JW, Serwaa D, Ayepola F, Ouédraogo JCRP. Characterization of patients with chronic kidney disease admitted at Edward Francis Small Teaching Hospital in the Gambia : a descriptive cross-sectional study. Pan African Med J. 2020;2:15.
Alssageer MA, Saad MM, Mosbah OM. Prevalence of comorbidities , polypharmacy and drug-related problems among hospitalized patients with chronic kidney disease. Mediterr J Pharm Pharm Sci. 2023;3(1):51-63.
T Tannor EK, Sarfo FS, Mobula LM, Sarfo‑Kantanka O, Adu‑Gyamfi R, Plange‑Rhule J. Prevalence and predictors of chronic kidney disease among Ghanaian patients with hypertension and diabetes mellitus : A multicenter cross ‐ sectional study. J Clin Hypertens. 2019;21(10):1542-50.
Hoogeveen EK. The Epidemiology of Diabetic Kidney Disease. Kidney Dial. 2022;2:433-42.
Van der Walt I, Swanepoel CR, Mahala B, Meyers AM. Important complications of chronic kidney disease. S Afr Med J. 2015;105(4):321-6.
Hayward S, Hole B, Denholm R, Duncan P, Morris JE, Fraser SDS, et al. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease : results from the European Quality study. Nephrol Dial Transpl. 2020;36(3):503-11.
Bajait CS, Pimpalkhute SA, Sontakke SD, Jaiswal KM, Dawri A V. Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Indian J Pharmacol. 2014;46(1):36-9.
Ahlawat R, Sanjay D, Tiwari P. Pharmaceutical Care and Health Systems Drug Utilization Pattern in Chronic Kidney Disease Patients at a Tertiary Care Public Teaching Hospital : Evidence from a Cross- Sectional Study. J Pharma Care Heal Sys. 2016;3(1):1-5.
Mathew S V, Uttangi S, Noble D, Ravi M, Mathew SK, Venkatesh JS. Drug Utilization Evaluation Study and Dose Adjustment in Patients with Kidney Disease in Tertiary Care Hospital To cite this article . Int J Biomed Eng Clin Sci. 2021;7(3):52-64.
Evans M, Lewis RD, Morgan AR, Whyte MB. A Narrative Review of Chronic Kidney Disease in Clinical Practice : Current Challenges and Future Perspectives. Adv Ther. 2022;39(1):33-43.
KDOQI. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. J Int Soc Nephrol. 2012;3(1). Available at: http://www.kidney-international.org. Accessed on 12 January 2026.
Tan K soon, Johnson DW. Managing the cardiovascular complications of chronic kidney disease. Aust Presciber. 2008;31(6):154-8.
Aoki J, Ikari Y. Cardiovascular Disease in Patients with End- Stage Renal Disease on Hemodialysis. Ann Vasc Dis. 2017;10(4):327-37.
Bezabhe WM, Kitsos A, Saunder T, Peterson GM, Bereznicki LR, Wimmer BC, et al. Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease. J Clin Med. 2020;9(783):1-19.
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):s1-87. Available at: www.kidney-international.org. Accessed on 12 January 2026.
Zoccali C, Tripepi G, Mallamaci F, Usvyat LS, Maddux FW, Stuard S. Choosing the right antihypertensive drug to avoid intradialytic hypotension. Clin Kidney J. 2025;18:47-54.
Rabbani R, Noel E, Boyle S, Balina H, Ali S, Fayoda B, et al. Role of Antihypertensives in End-Stage Renal Disease: A Systematic Review. Cureus. 2022;14(7):10-7.
Smits KPJ, Sidorenkov G, van Ittersum FJ, Waanders F, Bilo HJG, Navis GJ, et al. Prescribing quality in secondary care patients with different stages of chronic kidney disease : a retrospective study in the Netherlands. BMJ Open. 2019;9(7):e025784.
KDIGO. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.
Medscape. WebMD LLC. 2023. Available at: https://www.reference.medscape.com. Accessed on 12 January 2026.
Ang GY, Heng BH, Health P, Liew AST, Uk M, Chong PN. Quality of Care of Patients with Chronic Kidney Disease in National Healthcare Group Polyclinics from 2007 to 2011. Ann Acad Med. 2011;42(12):632-9.
Toshniwal SS, Avinash P, Loya A, Toshniwal T, Kumar S, Acharya S. The Role of Statins in Managing Chronic Kidney Disease : A Comprehensive Review. Int J Nephrol Renovasc Dis. 2021;14:45-54.
European Medicines Agency. Restriction of Combined Use of Medicines Affecting the Renin-Angiotensin System (RAS). European Medicines Agency. 2011;44. Available at: https://www.ema.europa.eu. Accessed on 12 January 2026.
Downloads
Published
How to Cite
Issue
Section
